-
NCCU 2025丨Prof. Shan Zheng: Piercing Through the Pink — How to Overcome Diagnostic and Prognostic Challenges in Eosinophilic Renal Tumors?
Editor’s note: The incidence of genitourinary cancers in China has continued to rise, with prostate, bladder, and kidney cancers ranking among the most common malignancies. Among them, eosinophilic renal tumors…
-
Professor Darren Poon at ESMO Asia: Liquid Biopsy Ushers in a New Era of Precision Prostate Cancer Care in China
Editor’s note: With the rapid evolution of next-generation sequencing (NGS) technologies in recent years, liquid biopsy has become a practical tool for prostate cancer assessment. It enables earlier detection and…
-
ESMO Asia 2025 | Professor George Lau: HR 0.60！STRIDE regimen Chinese population data impressively unveiled, dual immunotherapy efficacy significantly
From December 5 to 7, 2025, the highly anticipated European Society for Medical Oncology Asia Congress (ESMO Asia 2025) was grandly held in Singapore. During the Mini Oral Session: Gastrointestinal Tumours, Professor George Lau, Chairman of the Hong Kong Humanity Medical Group and Director of the Humanity Medical Clinical Research CenterSenior Consultant in Gastroenterology and…
-
SIBCS 2025丨GBG Chair Sibylle Loibl’s Plenary Lecture: Precision Treatment of Triple-Negative Breast Cancer in the ADC Era
Editor’s Note: Triple-negative breast cancer (TNBC) is a heterogeneous disease that historically had limited treatment options. Driven by rapid advances in antibody–drug conjugate (ADC) technology, the therapeutic landscape has seen…
-
ASH Expert Commentary | Professor Wenbin Qian: Advances in Cellular Immunotherapy — From “Revolutionary Therapy” to a “Diversified Treatment Platform”
Cellular immunotherapy has achieved revolutionary breakthroughs in hematologic malignancies and brought new survival opportunities to patients with relapsed or refractory disease. Autologous CAR-T cells have shown remarkable efficacy in lymphoma,…
-
ASH China Voice | Prof. Jian Huang’s Team: Innovative Treatment Strategies and Mutation Profiling in MPN and CML
From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando, USA. As the largest and most influential global conference in hematology, ASH annually…
-
ASH China Voice | Prof. Yang Liang’s Team Reveals FLT3/ITD-Driven AML Mechanism and New Predictive/Therapeutic Strategies in CLL
From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando, bringing together the latest global advances in hematologic research and clinical practice. Multiple…
-
ASH China Voice | Jia Wei’s Team Presents Seven Studies at ASH 2025, Advancing Multi-Dimensional Exploration of Therapeutic Bottlenecks in Hematologic
From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando. As the world’s most influential and comprehensive academic event in hematology, ASH annually gathers tens of thousands of experts to present breakthroughs spanning basic research to clinical innovation. This year, the team led by Professor Jia Wei of…
Connecting Medical Expertise through Media